Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for details on Kewaunee Scientific’s latest laboratory furniture contracts or wondering how steel prices affect its margins? This SEC filings hub brings every disclosure together, so you can move from question to insight in minutes.
Start with the Kewaunee Scientific annual report 10-K simplified section: our AI pinpoints backlog shifts, segment revenue from fume hoods vs. modular systems, and geographic risk factors—no need to scan 200 pages. Prefer quarter-to-quarter trends? The Kewaunee Scientific quarterly earnings report 10-Q filing page pairs raw numbers with narrative summaries that highlight material cost swings and project pipeline updates.
Real-time alerts keep you ahead of ownership moves. Track Kewaunee Scientific insider trading Form 4 transactions the moment they hit EDGAR. Our dashboard also groups Kewaunee Scientific Form 4 insider transactions real-time by executive, making it easy to spot buying before key bids or product launches.
Need context on sudden announcements? The platform’s AI explains every Kewaunee Scientific 8-K material events explained entry—from facility shutdowns to leadership changes—in plain language. For governance aficionados, the Kewaunee Scientific proxy statement executive compensation tab links pay packages to performance metrics, while AI flags noteworthy changes in option grants.
Across all filings you’ll see quick links like “understanding Kewaunee Scientific SEC documents with AI” and “Kewaunee Scientific earnings report filing analysis,” designed for analysts, portfolio managers, and supply-chain watchers alike. Every document is time-stamped, searchable, and supported by concise AI-powered summaries that turn dense disclosures into clear action points.
Donald T. Gardner III, Chief Financial Officer and director, reported a sale of 3,000 shares of Kewaunee Scientific Corp (KEQU) on
Form 144 notice for Kewaunee Scientific Corp. (ticker KEQU) reports a proposed sale of 3,000 common shares through Fidelity Brokerage Services LLC with an indicated aggregate market value of
Elizabeth D. Phillips, listed as a director and Vice President - Human Resources of Kewaunee Scientific Corp (KEQU), reported insider sales on 10/02/2025. The filing shows a sale of 6,877 shares at a weighted-average price of $43.20 (price range $43.05–$43.95), followed by an additional sale of 3 shares at $44.20. After the transactions the reporting person beneficially owned 8,251 shares and then 8,248 shares (direct ownership). The Form 4 was signed by an attorney-in-fact, Donald T. Gardner III. The filer also states availability of per-price purchase breakdown upon request.
Kewaunee Scientific director and President/CEO Thomas David Hull III reported a sale of 1,000 shares of the company's common stock on 10/01/2025 at a weighted average price of $43.09 per share, with the reported price range between $43.00 and $43.22. Following the sale, Mr. Hull beneficially owns 38,719 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. The filing includes a statement that the reporting person will provide, upon request, the number of shares bought at each separate price within the disclosed range.
Kewaunee Scientific Corp (KEQU) filed a Form 144 reporting a proposed sale of 6,880 shares of common stock to be sold through Ameriprise Financial Services, LLC on 10/01/2025. The filing states an aggregate market value of $293,432.00 and lists 2,865,694 shares outstanding. The securities were acquired on 10/01/2025 as equity compensation from Kewaunee Scientific Corporation, with payment recorded as equity compensation on the same date. The filer reports no securities sold in the past three months and includes the standard signature representation that no undisclosed material adverse information is known.
KEWAUNEE SCIENTIFIC CORP (/DE/, KEQU) reporting person Thomas David Hull III, who serves as President, CEO and a director, reported a sale of common stock on 09/29/2025. The Form 4 shows 1,854 shares were sold at a weighted average price of $43.42, with the trade price range disclosed as $43.00 to $43.85. After the sale, Hull beneficially owns 39,719 shares, held directly. The form was signed by an attorney-in-fact on 10/01/2025. The filing includes an undertaking to provide detailed per-price purchase information on request.
Form 144 notice by an insider of Kewaunee Scientific Corp (KEQU) discloses a proposed sale of 1,000 common shares through Fidelity Brokerage Services (Boston) with an aggregate market value of $42,720, and lists prior open-market sales by the same person totaling 5,000 shares across five transactions between September 18–29, 2025, generating gross proceeds shown for each trade. The 1,000 shares were acquired as a stock award on June 30, 2024 and were issued as compensation. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Thomas David Hull III, President, CEO and director of Kewaunee Scientific Corp (KEQU), reported two open-market sales of common stock on September 23-24, 2025. He sold 721 shares on 09/23/2025 at a weighted-average price shown as $44 and an additional 1,000 shares on 09/24/2025 at a weighted-average price shown as $43.62. After the September 23 trade his beneficial ownership was 42,573 shares and after the September 24 trade it was 41,573 shares. The form was signed by an attorney-in-fact on 09/24/2025. The filing includes a note that reported prices are weighted averages and that the filer will provide breakdowns on request.
Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.
Campbell John Jette, identified as a director of Kewaunee Scientific Corp (KEQU), filed an initial Section 16 Form 3 reporting the transaction date 09/10/2025. The filing states no securities are beneficially owned by the reporting person and includes a power of attorney (Exhibit 24) with the form signed by an attorney-in-fact on 09/11/2025. This is an initial ownership disclosure showing the director currently holds no reportable equity.
FAQ
What is the current stock price of Kewaunee Scienti (KEQU)?
What is the market cap of Kewaunee Scienti (KEQU)?
